Seminars in Ophthalmology · Nov 18, 2026
GLP-1 Receptor Agonists and the Risk of Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis
By Alotaibi HA, Alshaibani AK, Alzahrani RM et al.
Topic Whether glucagon-like peptide-1 receptor agonist (GLP-1RA) use is associated with a lower risk of incident glaucoma or ocular hypertension (OHT) in adults, and whether the association differs by diabetes status or comparator. Clinical relevance Glaucoma is the leading cause of irreversible blindness worldwide, and every licensed treatment targets lowering intraocular pressure (IOP); none protects retinal ganglion cells directly. GLP-1RAs are widely prescribed and have been proposed to be neuroprotective, so whether this class of medication alters glaucoma risk matters at prescribing and to the search for pressure-independent treatment. Four earlier meta-analyses found no significant association but pooled non-equivalent comparators. Methods Systematic review and meta-analysis of observational studies, following PRISMA 2020 and registered on PROSPERO (CRD420251082642). PubMed was searched on 15 April 2026 and updated to 30 August 2026, with CENTRAL, Europe PMC, the first 100 Google Scholar results and bidirectional citation tracking as supplementary sources. Eligible studies were retrospective cohort or nested case-control studies of GLP-1RA exposure with incident glaucoma, OHT or IOP change as the outcome and with adjustment for confounding. Two reviewers screened, extracted and applied ROBINS-I. Estimates were pooled by DerSimonian-Laird random effects, with a Hartung-Knapp-Sidik-Jonkman (HKSJ) interval, a 95% prediction interval and GRADE. Results Ten studies were included from 406 screened records. Six cohorts covering 225,814 matched or analysed patients were pooled. GLP-1RA use was associated with a lower incidence of recorded glaucoma or OHT (pooled hazard ratio 0.69, 95% CI 0.59 to 0.80; HKSJ CI 0.56 to 0.85), but heterogeneity was 58.5%, the 95% prediction interval (0.44 to 1.08) included no effect, and certainty was low. The association held after all TriNetX studies were removed (0.78, 0.71 to 0.85) and after restriction to open-angle outcomes (0.66, 0.53 to 0.82). Diabetes status, comparator type and data platform could not be separated. Conclusion Low-certainty observational evidence suggests GLP-1RA use is not associated with a higher risk of glaucoma or OHT and may be associated with a lower one. Confounding by indication, coded outcome ascertainment and a prediction interval that includes no effect mean protection has not been shown. The findings support reassurance and the randomized trial under way.
doi.org/10.1080/08820538.2026.2767204PubMed 43052191Interventions